-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In patients with acute lymphoblastic leukemia (ALL) who have received allogeneic hematopoietic stem cell transplantation (allo-HSCT), the compatibility of the lebucannum-based protocol with the systemic radiation (TBI)-based protocol remains controversial
This is an open-labeled, randomized Phase 3 clinical trial jointly conducted by 13 hospitals in China, recruiting ALL patients
Between January 2016 and February 2020, 275 patients were assigned to each of the two groups, with 273 in the BuCy group and 272 in the TBI-Cy group included in the assessment
In summary, for adult patients with B-cell ALL who intend to receive HLA-matched allo-HSCT for the standard risk of obtaining the first complete remission, the BuCy protocol has a non-inferior effect and safety profile
Original Source:
Haiyan Zhang, et al.